ImaBiotech

ImaBiotech provides molecular imaging services and products aimed at strengthening the development of new drugs through innovative patented technologies. ImaBiotech supports the pharmaceutical industry with innovative imaging services to more accurately predict which treatments will work in stratified populations. ImaBiotech is a contract research organization with facilities in Boston and France. The company offers innovative services for drug research, providing better evaluation of drug efficacy and toxicity from preclinical to clinical stages, and manufacturing better and safer drugs. Services are based on various imaging technologies combined with quantitative mass spectrometry techniques, which ImaBiotech has developed and continuously improved. Quantitative mass spectrometry has evolved over decades, allowing for the detection of elements and molecules without labeling. Through multiple patents, ImaBiotech has advanced the quantitative aspect, establishing itself as a global leader in this field. QMSI is a game-changer for the pharmaceutical industry across all therapeutic areas. While current technologies provide global information, this molecular technology offers deeper insights into drug localization and pharmacological effects to restore diseased tissues and damaged cells. This enhances the interpretation of drug efficacy and toxicity, improves drugs, and shortens time to market. Thanks to our patents, we have developed two software programs, Quantinetix and Multiaging, to interpret pharmacology in tissues.